Education
About Us
Working with TipRanks
Follow Us
Polyrizon Ltd. (PLRZ)
:PLRZ
PLRZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.55 - $1,200.00
Previous CloseN/A
Volume125.93K
Average Volume (3M)7.19M
Market Cap
$6.29M
Enterprise ValueN/A
Total Cash (Recent Filing)$2.55M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.02
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding5,989,294
10 Day Avg. Volume659,695
30 Day Avg. Volume7,188,317
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Polyrizon Ltd. News
PLRZ FAQ
What was Polyrizon Ltd.’s price range in the past 12 months?
Polyrizon Ltd. lowest stock price was $0.55 and its highest was $1200.00 in the past 12 months.
What is Polyrizon Ltd.’s market cap?
Polyrizon Ltd.’s market cap is $6.29M.
When is Polyrizon Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Polyrizon Ltd.’s earnings last quarter?
Currently, no data Available
Is Polyrizon Ltd. overvalued?
According to Wall Street analysts Polyrizon Ltd.’s price is currently Overvalued.
Does Polyrizon Ltd. pay dividends?
Polyrizon Ltd. does not currently pay dividends.
What is Polyrizon Ltd.’s EPS estimate?
Polyrizon Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Polyrizon Ltd. have?
Polyrizon Ltd. has 5,989,294 shares outstanding.
What happened to Polyrizon Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Polyrizon Ltd.?
Currently, no hedge funds are holding shares in PLRZ
Company Description
Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Polyrizon Ltd. (PLRZ) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
GRI Bio
―
Protagenic Therapeutics
―
Ownership Overview
―
Insiders
―
Mutual Funds
5.79% Other Institutional Investors
94.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---